Overview
OncoDNA offers NGS testing solutions including OncoDEEP® (solid biopsy), OncoSELECT® (liquid biopsy), and clinical data intelligence platforms. The company serves oncology laboratory professionals, pharma companies, and healthcare institutions to guide treatment decisions and precision patient enrollment.
Funding & milestones
3 events found for OncoDNA · 2016–2023
Series AVenture / equity1 source€7.7M
Reported amount €7,700,000
Participating investor Ackermans & van Haaren announces EUR 7.7m equity; later company history rounds this to EUR 8m.
InvestorsAckermans & van HaarenSeries BVenture / equity1 source€19M
Reported amount €19,000,000
Investor-hosted company release confirms completed EUR 19m Series B.
InvestorsVesalius Biocapital IIISwisscanto InvestSFPI-FPIMCPH BankInventuresSambrinvestSofinimSRIWSeries CVenture / equity1 source€6.5M
Reported amount €6,500,000
Company release announces EUR 6.5m Series C, entirely subscribed by existing shareholders.
InvestorsWallonie EntreprendreVesalius BioCapital IIIAckermans & van HaarenSwisscantoCPH BankSFPISambrinvest
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Key people
In the news
- How reliable is a ctDNA panel across labs and sequencers? We just published the 𝗢𝗻𝗰𝗼𝗦𝗘𝗟𝗘𝗖𝗧® white paper: a multi-center validation of our 74-gene liquid biopsy panel, run across four European laboratories (Belgium, Germany, Spain and France). What the paper covers: • SNVs, indels, CNVs and fusions detected with a single hybrid-capture workflow • Limit of detection of 0.25% VF for SNVs and indels, and 6 copies for CNVs • Results on Illumina, with comparison data on Element AVITI and MGI T1 • Five days from
- How reliable is a ctDNA panel across labs and sequencers? We just published the 𝗢𝗻𝗰𝗼𝗦𝗘𝗟𝗘𝗖𝗧® white paper: a multi-center validation of our 74-gene liquid biopsy panel, run across four European laboratories (Belgium, Germany, Spain and France). What the paper covers: • SNVs, indels, CNVs and fusions detected with a single hybrid-capture workflow • Limit of detection of 0.25% VF for SNVs and indels, and 6 copies for CNVs • Results on Illumina, with comparison data on Element AVITI and MGI T1 • Five days from
- How can we detect cancer signals in the blood ? A single blood tube can carry several signals from cancer. Swipe through to discover the four most talked about: • 𝗰𝗳𝗗𝗡𝗔: all the cell-free DNA circulating in the blood, from healthy and cancerous cells alike • 𝗰𝘁𝗗𝗡𝗔: the fraction of cfDNA released by tumour cells • 𝗖𝗧𝗖𝘀: whole cancer cells that have detached from a tumour • 𝗘𝘅𝗼𝘀𝗼𝗺𝗲𝘀: tiny particles carrying RNA, proteins and DNA fragments Each one tells a different part of the story. Among them, circulating DNA
- 𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗺𝗮𝗸𝗲 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗲𝘃𝗲𝗻 𝗺𝗼𝗿𝗲 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗹𝗲 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝗯𝘆 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿? That one question sums up our four days at #ESMO. Here’s our wrap-up: 🤝 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝘁 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 𝗼𝗳 𝗲𝘃𝗲𝗿𝘆 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 Oncologists, pathologists, partners and distributors came to the OncoDNA booth with a shared ambition: to find ways to collaborate, accelerate our innovations and bring precision medicine even closer to
- Day 2 at #ESMO and the energy keeps rising! The conversations with oncologists, pathologists and researchers at our booth are truly inspiring, and the interest in our advanced precision oncology solutions is exceeding all expectations. Thank you to everyone stopping by! Here’s what’s getting people talking: 🔬 OncoDEEP® Kit, our comprehensive tissue-based genomic profiling solution, soon available with a large RNA panel to capture fusions and expression signatures, giving an even richer picture of each tumour. 🎯 OncoSELECT®,
- To face our future challenges and reinforce the QA Department - We’re hiring a Junior Quality Assistant . Are you passionate about quality systems and excited by the challenges of medical software? Do you enjoy working closely with technical and production teams and having a real impact in a growing organization? This role might be for you 👇 https://lnkd.in/eXDhic-y
- Last week, 𝗢𝗻𝗰𝗼𝗗𝗡𝗔 brought together a diverse group of stakeholders in Ireland to tackle a critical question: What is the current position and future need of the genomic record in oncology and beyond? Over a shared meal, this multi-professional group reflected on the realities of today’s genomic records, weighing the positives against the clear areas for improvement. We looked at the ecosystem from different angles: • 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗠𝗮𝗸𝗶𝗻𝗴: What do multi-disciplinary teams actually need from
- How does breast cancer evolve and how can understanding that evolution help uncover new therapeutic opportunities? On International Breast Cancer Day, we’re shining a spotlight on AURORA, an international research programme dedicated to understanding the molecular evolution of metastatic breast cancer. Launched in 2014, AURORA investigates the molecular changes that occur as the disease progresses. Building on these discoveries, AURORA 2 further explores the mechanisms driving disease progression and treatment resistance. At
Alumni 2 went on to found or lead
Christophe Van HuffelNorth-American Pharma Business Prospection→Co-Founder and CSO at OncoRNA
Jean-Pol DetiffeFounder & CEO→co-Founder OncoRNA www.oncorna.eu at OncoRNA
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.